Companies: 10,795·Total market cap: $144.5T
Sensei Biotherapeutics, Inc.

Sensei Biotherapeutics, Inc.

SNSENASDAQHealthcare● Active
$13.00
$-1.65(-11.26%)
Market Cap$17445220
P/E Ratio
52W High$36.76
52W Low$5.6

Sensei Biotherapeutics, Inc. (SNSE) PE Ratio — Current & Historical Data

Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.

snse · pe ratio · data through Dec 31, 2025

Core PE Ratio Metrics

Trailing 12 months · TTM

The price-to-earnings (P/E) ratio for Sensei Biotherapeutics, Inc. (SNSE) measures how much investors pay for each dollar of the company's trailing earnings. SNSE's current PE ratio of N/A is calculated by dividing its stock price of $13.00 by its TTM earnings per share of -$142.43.

N/A
P/E Ratio (TTM)N/A — Company is not profitable (TTM)

Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31

Forward P/E
N/A
FY2027 est. EPS $-6.52
Based on 2 analysts
EPS (TTM)
-$142.43
TTM · diluted EPS
PEG Ratio
0.00
Below 1.0 · Growth adjusted
Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Sensei Biotherapeutics, Inc. SEC 10-K & 10-Q filings · US GAAPUpdated: 2026-06-09

PE Ratio History

2018 – 2025 · Annual
PE Ratio (TTM)
EPS (Annual)

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)

PE Ratio vs Peers

Biotechnology · 6 peers · Annual PE
CompanyMarket CapPE (Annual)vs AvgEPS (TTM)
Sensei Biotherapeutics, Inc.
Sensei Biotherapeutics, Inc.You
SNSE
$17MN/A-$142.43
AEON Biopharma, Inc.
AEON Biopharma, Inc.
AEON
$9MN/A-$3.95
Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc.
BOLT
$9MN/A-$17.85
Cingulate Inc.
Cingulate Inc.
CING
$27MN/A-$4.13
Cellectar Biosciences, Inc.
Cellectar Biosciences, Inc.
CLRB
$8MN/A-$8.35
Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc.
COCP
$11MN/A-$0.78
Dogwood Therapeutics, Inc.
Dogwood Therapeutics, Inc.
DWTX
$3MN/A-$4.17

* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio

Annual PE Ratio History

Showing 8 of 8 years
Fiscal Year EndPE RatioEPS (TTM)YoY ChangePE vs Max
2025-12-31Latest
FY2025
$-16.72
2024-12-31
FY2024
$-1.20
2023-12-31
FY2023
$-1.22
2022-12-31
FY2022
$-1.58
2021-12-31
FY2021
$-1.33
2020-12-31
FY2020
$-0.66
2019-12-31
FY2019
$-0.57
2018-12-31
FY2018
$-19.03

▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API

About PE Ratio & Methodology

The price-to-earnings (P/E) ratio for Sensei Biotherapeutics, Inc. (SNSE) measures how much investors pay for each dollar of the company's trailing earnings. SNSE's current PE ratio of N/A is calculated by dividing its stock price of $13.00 by its TTM earnings per share of -$142.43.

PE Ratio = Stock Price ÷ EPS (TTM)
= $13.00 ÷ -$142.43 = N/A
TTMTrailing Twelve Months — sum of the most recent 4 quarterly EPS figures
Forward PEStock price ÷ analyst consensus EPS estimate for the next fiscal year
PEGPE ÷ earnings growth rate — values below 1.0 suggest growth may justify the premium
Figures tie to SEC 10-K/10-Q and FMP ratio endpoints where noted.

Frequently asked questions

SNSE pe ratio · 6 questions

SNSE's current PE ratio is N/A as of 2026-06-09, based on a stock price of $13.00 and TTM EPS of -$142.43. Data sourced from Financial Modeling Prep via SNSE's SEC 10-K and 10-Q filings.

SNSE PE ratioWhat is SNSE PE ratioCurrent PE ratio of SNSESNSE PE ratio today

Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Sensei Biotherapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09